(90)Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

Despite significant advances in the treatment of Hodgkin’s lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Proc Natl Acad Sci U S A
Asıl Yazarlar: Janik, John E., Morris, John C., O’Mahony, Deirdre, Pittaluga, Stefania, Jaffe, Elaine S., Redon, Christophe E., Bonner, William M., Brechbiel, Martin W., Paik, Chang H., Whatley, Millie, Chen, Clara, Lee, Jae-Ho, Fleisher, Thomas A., Brown, Maggie, White, Jeffrey D., Stewart, Donn M., Fioravanti, Suzanne, Lee, Cathryn C., Goldman, Carolyn K., Bryant, Bonita R., Junghans, Richard P., Carrasquillo, Jorge A., Worthy, Tat’Yana, Corcoran, Erin, Conlon, Kevin C., Waldmann, Thomas A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2015
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620907/
https://ncbi.nlm.nih.gov/pubmed/26438866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1516107112
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller